RecruitingPhase 1Phase 2NCT05790889

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

A Phase IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of the Blood-stage Malaria Vaccine Candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in Infants Aged 5-17 Months in Burkina Faso.

Sponsor

University of Oxford

Enrollment

480 participants

Start Date

Apr 3, 2023

Study Type

INTERVENTIONAL

Conditions

Malaria,Falciparum

Summary

This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso

Eligibility

Min Age: 5 MonthsMax Age: 17 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called RH5.1 10μg adjuvated with 50μg Matrix-M, a biological treatment called RH5.2 5μg adjuvated with 50μg Matrix-M, and others for people with malaria,falciparum. The study is currently recruiting participants at 1 location. People eligible for this study include aged 5 Months to 17 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.